# NVIDIA–Lilly $1B Co-Innovation Lab — Silicon Married to the Wet Lab

Times of AI Desk · 2026-01-12 · Industry

[https://timesof.ai/2026/01/nvidia-eli-lilly-ai-co-innovation-lab-drug-discovery](https://timesof.ai/2026/01/nvidia-eli-lilly-ai-co-innovation-lab-drug-discovery)

> NVIDIA and Eli Lilly (Jan 12, JPM Healthcare): AI co-innovation lab with up to $1B joint investment over five years in the Bay Area—Lilly biologists beside NVIDIA engineers on BioNeMo and Vera Rubin for closed-loop wet/dry discovery. Biggest AI capex wave includes pharma benches, not only chatbots.

The biggest AI capex wave is no longer only hyperscaler chatbots—it is **silicon married to wet-lab biology**. NVIDIA–Lilly’s proprietary blueprint: co-locate domain experts with GPU builders and close the loop between experiment and model.

**NVIDIA** and **Eli Lilly** announced January 12 at the **J.P. Morgan Healthcare Conference** an **AI co-innovation lab** for drug discovery and development, jointly investing **up to $1 billion over five years** in infrastructure, workforce, and compute. Location: San Francisco Bay Area / South San Francisco lab pairing Lilly scientists (biology, medicine) with NVIDIA AI engineers. Operating model: “scientist in the loop” / closed-loop **agentic wet labs** and **computational dry labs**, aiming for **24/7** AI-assisted experimentation. Stack: **NVIDIA BioNeMo** and **Vera Rubin**-class architecture. Mission: accelerate discovery, improve clinical development models, eventually robotics/physical AI for discovery and production. Work to begin early 2026; framed as first-of-its-kind pharma–chip co-innovation lab at this scale.

## Claims vs checks

Investment ceiling, lab design, and stack names are **NVIDIA + Lilly primary**. “Up to $1B over five years” is a joint commitment envelope—not a single equity check already wired. Fierce Biotech / Bloomberg JPM coverage same day.

## Limits

- Co-innovation labs are multi-year; near-term pipeline impact is not promised in the release.
- Closed-loop wet/dry automation faces regulatory and data-integrity constraints.
- Vera Rubin-class infra availability timelines are vendor roadmaps.

## Sources

- NVIDIA investor newsroom: “NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery in the Age of AI” (January 12, 2026). Primary.
- Eli Lilly / Fierce Biotech / Bloomberg contemporaneous JPM coverage (January 12, 2026).